Effettuare il login Iscriviti gratis

Neovacs S.A Ret. sull'equità

Cos'è Ret. sull'equità di Neovacs S.A?

Ret. sull'equità di Neovacs S.A. è -11.05%

Qual è la definizione di Ret. sull'equità?



Il rendimento del capitale netto è una misura della redditività di un'impresa in relazione al valore contabile del capitale azionario. Viene calcolato dividendo l'utile netto dell'anno fiscale per il capitale azionario totale.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. sull'equità di aziende nel Health Care settore su EURONEXT rispetto a Neovacs S.A

Cosa fa Neovacs S.A?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Aziende con ret. sull'equità simili a Neovacs S.A